STILLWATER, Minn., March 9 /PRNewswire/ -- Spineology Inc. announced today that Donald R. Brattain was elected to the Company's Board of Directors, effective February 25, 2004.
Mr. Brattain is President of Brattain & Associates, LLC, a private company located in Minneapolis. In 1991, prior to founding his investment company, Mr. Brattain acquired Barefoot Grass Lawn Service, which he grew from $3.2 million in annual sales to over $100 million. He guided Barefoot through an LBO and IPO before the sale of the company in 1998. Mr. Brattain has chaired and/or served on the boards of six publicly traded companies, including Orthomet, an orthopedic implant company, and Everest Medical, a laparoscopic medical device company. Mr. Brattain no longer serves on the board of any public company but operates several private companies in which he has a majority ownership.
"Mr. Brattain is a valuable addition to our Board of Directors. His vast experience in raising capital, managing resources and building value in companies, large and small, are important assets that he brings to Spineology," said Douglas E. King, Chief Executive Officer of Spineology.
About Spineology Inc.
Spineology is a developer of proprietary technologies to be manufactured and marketed to the global spine implant market. The company has begun U.S. commercialization of OptiMesh, a bone graft containment and reinforcement system for use in vertebral body (intrabody) defects of the spine.
This press release contains forward-looking statements by Spineology regarding its expectations as to its OptiMesh products and other aspects of its business. Such statements are based on its current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, its history of operating losses and its need for additional funds, as well as the risks and uncertainties in preclinical and clinical trial results, gaining regulatory approvals, scaling-up manufacturing, market acceptance, the sales levels of its products, research and development, competition and other risk factors. Spineology undertakes no obligation to publicly update any forward-looking statements.
Contact: Douglas E. King, Chief Executive Officer, Spineology, 651-351-1011